Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 31Fluorouracil 31Leucovorin 29Irinotecan 23Cetuximab 20Bevacizumab 16Capecitabine 13Gemcitabine 11pembrolizumab 8Folfox protocol 7Cisplatin 7Carboplatin 7Paclitaxel 6Nivolumab 6Cyclophosphamide 6trifluridine tipiracil drug combination 5cediranib 5Erlotinib Hydrochloride 5adagrasib 4Ipilimumab 4IFL protocol 4Floxuridine 4Bortezomib 4veliparib 3trametinib 3sargramostim 3poly ICLC 3binimetinib 3Trifluridine 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colonic Neoplasms × pidilizumab × Clear all
NCT01386502 2017-07-02

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡